Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

HMS faculty, help us improve the algorithms in Profiles by uploading your CV!

Jerrold Frank Rosenbaum, M.D.

Co-Author

This page shows the publications co-authored by Jerrold Rosenbaum and Andrew Nierenberg.
Connection Strength

2.594
  1. Dopaminergic agents and stimulants as antidepressant augmentation strategies. J Clin Psychiatry. 1998; 59 Suppl 5:60-3; discussion 64.
    View in: PubMed
    Score: 0.180
  2. Social adjustment does not predict depressive relapse during continuation fluoxetine therapy. J Affect Disord. 1995 May 17; 34(2):73-7.
    View in: PubMed
    Score: 0.150
  3. Assuring that double-blind is blind. Am J Psychiatry. 2010 Mar; 167(3):250-2.
    View in: PubMed
    Score: 0.104
  4. A Double-blind, randomized trial of St John's wort, fluoxetine, and placebo in major depressive disorder. J Clin Psychopharmacol. 2005 Oct; 25(5):441-7.
    View in: PubMed
    Score: 0.077
  5. Hypericum extract in patients with MDD and reversed vegetative signs: re-analysis from data of a double-blind, randomized trial of hypericum extract, fluoxetine, and placebo. Int J Neuropsychopharmacol. 2005 Jun; 8(2):215-21.
    View in: PubMed
    Score: 0.072
  6. Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol Psychiatry. 2003 Jun 01; 53(11):1028-42.
    View in: PubMed
    Score: 0.065
  7. Axis III disorders in treatment-resistant major depressive disorder. Psychiatry Res. 2003 May 30; 118(2):183-8.
    View in: PubMed
    Score: 0.065
  8. Treatment-resistant depression and Axis II comorbidity. Psychother Psychosom. 2002 Sep-Oct; 71(5):269-74.
    View in: PubMed
    Score: 0.062
  9. Double-blind study of high-dose fluoxetine versus lithium or desipramine augmentation of fluoxetine in partial responders and nonresponders to fluoxetine. J Clin Psychopharmacol. 2002 Aug; 22(4):379-87.
    View in: PubMed
    Score: 0.062
  10. Body dysmorphic disorder in outpatients with major depression. J Affect Disord. 2002 May; 69(1-3):141-8.
    View in: PubMed
    Score: 0.061
  11. Strategies for treatment of SSRI-associated sexual dysfunction: a survey of an academic psychopharmacology practice. Harv Rev Psychiatry. 2002 Mar-Apr; 10(2):109-14.
    View in: PubMed
    Score: 0.060
  12. Treatment resistant depression and axis I co-morbidity. Psychol Med. 2001 Oct; 31(7):1223-9.
    View in: PubMed
    Score: 0.058
  13. Timing of onset of antidepressant response with fluoxetine treatment. Am J Psychiatry. 2000 Sep; 157(9):1423-8.
    View in: PubMed
    Score: 0.054
  14. Partial response, nonresponse, and relapse with selective serotonin reuptake inhibitors in major depression: a survey of current "next-step" practices. J Clin Psychiatry. 2000 Jun; 61(6):403-8.
    View in: PubMed
    Score: 0.053
  15. Fenfluramine challenge in unipolar depression with and without anger attacks. Psychiatry Res. 2000 Apr 24; 94(1):9-18.
    View in: PubMed
    Score: 0.053
  16. Anxiety disorders in major depression. Compr Psychiatry. 2000 Mar-Apr; 41(2):97-102.
    View in: PubMed
    Score: 0.052
  17. Dysfunctional attitudes and poor problem solving skills predict hopelessness in major depression. J Affect Disord. 1999 Sep; 55(1):45-9.
    View in: PubMed
    Score: 0.050
  18. Patterns of axis I comorbidity in early-onset versus late-onset major depressive disorder. Biol Psychiatry. 1999 Jul 15; 46(2):202-11.
    View in: PubMed
    Score: 0.050
  19. Residual symptoms in depressed patients who respond acutely to fluoxetine. J Clin Psychiatry. 1999 Apr; 60(4):221-5.
    View in: PubMed
    Score: 0.049
  20. Outcome definitions and predictors in depression. Psychother Psychosom. 1998 Jul-Oct; 67(4-5):266-70.
    View in: PubMed
    Score: 0.047
  21. Course and treatment of atypical depression. J Clin Psychiatry. 1998; 59 Suppl 18:5-9.
    View in: PubMed
    Score: 0.045
  22. Emergence of adverse events following discontinuation of treatment with extended-release venlafaxine. Am J Psychiatry. 1997 Dec; 154(12):1760-2.
    View in: PubMed
    Score: 0.045
  23. Major depressive subtypes and treatment response. Biol Psychiatry. 1997 Oct 01; 42(7):568-76.
    View in: PubMed
    Score: 0.044
  24. A preliminary study on the efficacy of sertraline and imipramine on anger attacks in atypical depression and dysthymia. Psychopharmacol Bull. 1997; 33(1):101-3.
    View in: PubMed
    Score: 0.042
  25. Consumption of alcohol, nicotine, and caffeine among depressed outpatients. Relationship with response to treatment. Psychosomatics. 1996 Nov-Dec; 37(6):518-22.
    View in: PubMed
    Score: 0.041
  26. Hostility changes following antidepressant treatment: relationship to stress and negative thinking. J Psychiatr Res. 1996 Nov-Dec; 30(6):459-67.
    View in: PubMed
    Score: 0.041
  27. Are neurovegetative symptoms stable in relapsing or recurrent atypical depressive episodes? Biol Psychiatry. 1996 Oct 15; 40(8):691-6.
    View in: PubMed
    Score: 0.041
  28. Cynicism, hostility, and suicidal ideation in depressed outpatients. J Nerv Ment Dis. 1996 Oct; 184(10):607-10.
    View in: PubMed
    Score: 0.041
  29. Patterns of personality disorder comorbidity in early-onset versus late-onset major depression. Am J Psychiatry. 1996 Oct; 153(10):1308-12.
    View in: PubMed
    Score: 0.041
  30. Are study dropouts different from completers? Biol Psychiatry. 1996 Oct 01; 40(7):668-70.
    View in: PubMed
    Score: 0.041
  31. Hypochondriacal concerns in depressed outpatients. Psychosom Med. 1996 Jul-Aug; 58(4):314-20.
    View in: PubMed
    Score: 0.041
  32. Gender differences in Axis I comorbidity among depressed outpatients. J Affect Disord. 1996 Jun 05; 38(2-3):129-33.
    View in: PubMed
    Score: 0.040
  33. Fluoxetine treatment of anger attacks: a replication study. Ann Clin Psychiatry. 1996 Mar; 8(1):7-10.
    View in: PubMed
    Score: 0.040
  34. Early nonresponse to fluoxetine as a predictor of poor 8-week outcome. Am J Psychiatry. 1995 Oct; 152(10):1500-3.
    View in: PubMed
    Score: 0.038
  35. Relapse in patients on long-term fluoxetine treatment: response to increased fluoxetine dose. J Clin Psychiatry. 1995 Feb; 56(2):52-5.
    View in: PubMed
    Score: 0.037
  36. Patterns of improvement in depressive symptoms with fluoxetine treatment. Psychopharmacol Bull. 1995; 31(2):223-6.
    View in: PubMed
    Score: 0.037
  37. Conditional probability of response or nonresponse of placebo compared with antidepressants or St John's Wort in major depressive disorder. J Clin Psychopharmacol. 2013 Dec; 33(6):827-30.
    View in: PubMed
    Score: 0.034
  38. Personality and bipolar disorder: dissecting state and trait associations between mood and personality. Psychol Med. 2011 Aug; 41(8):1593-604.
    View in: PubMed
    Score: 0.028
  39. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006 Nov; 163(11):1905-17.
    View in: PubMed
    Score: 0.021
  40. Clinical and demographic features of atypical depression in outpatients with major depressive disorder: preliminary findings from STAR*D. J Clin Psychiatry. 2005 Aug; 66(8):1002-11.
    View in: PubMed
    Score: 0.019
  41. The relationship between serum folate, vitamin B12, and homocysteine levels in major depressive disorder and the timing of improvement with fluoxetine. Int J Neuropsychopharmacol. 2005 Dec; 8(4):523-8.
    View in: PubMed
    Score: 0.019
  42. Obesity among outpatients with major depressive disorder. Int J Neuropsychopharmacol. 2005 Mar; 8(1):59-63.
    View in: PubMed
    Score: 0.018
  43. Serum cholesterol in the continuation phase of pharmacotherapy with fluoxetine in remitted major depressive disorder. J Clin Psychopharmacol. 2004 Aug; 24(4):467-9.
    View in: PubMed
    Score: 0.018
  44. Serum folate, vitamin B12, and homocysteine in major depressive disorder, Part 1: predictors of clinical response in fluoxetine-resistant depression. J Clin Psychiatry. 2004 Aug; 65(8):1090-5.
    View in: PubMed
    Score: 0.018
  45. Serum folate, vitamin B12, and homocysteine in major depressive disorder, Part 2: predictors of relapse during the continuation phase of pharmacotherapy. J Clin Psychiatry. 2004 Aug; 65(8):1096-8.
    View in: PubMed
    Score: 0.018
  46. Effect of medical comorbidity on response to fluoxetine augmentation or dose increase in outpatients with treatment-resistant depression. Psychosomatics. 2004 May-Jun; 45(3):224-9.
    View in: PubMed
    Score: 0.017
  47. The prevalence and clinical correlates of anger attacks during depressive episodes in bipolar disorder. J Affect Disord. 2004 Apr; 79(1-3):291-5.
    View in: PubMed
    Score: 0.017
  48. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials. 2004 Feb; 25(1):119-42.
    View in: PubMed
    Score: 0.017
  49. Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder. J Clin Psychiatry. 2004 Feb; 65(2):217-21.
    View in: PubMed
    Score: 0.017
  50. Clinical and sociodemographic predictors of response to augmentation, or dose increase among depressed outpatients resistant to fluoxetine 20 mg/day. Acta Psychiatr Scand. 2003 Dec; 108(6):432-8.
    View in: PubMed
    Score: 0.017
  51. Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. Psychiatr Clin North Am. 2003 Jun; 26(2):457-94, x.
    View in: PubMed
    Score: 0.016
  52. Serum cholesterol and serotonergic function in major depressive disorder. Psychiatry Res. 2003 May 30; 118(2):137-45.
    View in: PubMed
    Score: 0.016
  53. Behavioral and emotional disturbances in the offspring of depressed parents with anger attacks. Psychother Psychosom. 2003 Mar-Apr; 72(2):102-6.
    View in: PubMed
    Score: 0.016
  54. Selecting methodologies for the evaluation of differences in time to response between antidepressants. J Clin Psychiatry. 2002 Aug; 63(8):694-9.
    View in: PubMed
    Score: 0.015
  55. A survey of prescribing practices in the treatment of depression. Prog Neuropsychopharmacol Biol Psychiatry. 2002 Jan; 26(1):177-87.
    View in: PubMed
    Score: 0.015
  56. Tryptophan depletion in SSRI-recovered depressed outpatients. Psychopharmacology (Berl). 2001 May; 155(2):123-7.
    View in: PubMed
    Score: 0.014
  57. An ideal trial to test differential onset of antidepressant effect. J Clin Psychiatry. 2001; 62 Suppl 4:34-6; discussion 37-40.
    View in: PubMed
    Score: 0.014
  58. A survey of prescribing preferences in the treatment of refractory depression: recent trends. Psychopharmacol Bull. 2001; 35(3):150-6.
    View in: PubMed
    Score: 0.014
  59. Strategies for managing depression refractory to selective serotonin reuptake inhibitor treatment: a survey of clinicians. Can J Psychiatry. 2000 Jun; 45(5):476-81.
    View in: PubMed
    Score: 0.013
  60. Compounds containing cytosolic choline in the basal ganglia: a potential biological marker of true drug response to fluoxetine. Am J Psychiatry. 1999 Oct; 156(10):1638-40.
    View in: PubMed
    Score: 0.013
  61. Efficacy of fluvoxamine in the treatment of major depression with comorbid anxiety disorders. J Clin Psychiatry. 1999 Sep; 60(9):580-3.
    View in: PubMed
    Score: 0.013
  62. Open study of the catechol-O-methyltransferase inhibitor tolcapone in major depressive disorder. J Clin Psychopharmacol. 1999 Aug; 19(4):329-35.
    View in: PubMed
    Score: 0.013
  63. Axis I and Axis II disorder comorbidity in unipolar depression with anger attacks. J Affect Disord. 1999 Jan-Mar; 52(1-3):217-23.
    View in: PubMed
    Score: 0.012
  64. Social phobia, avoidant personality disorder and atypical depression: co-occurrence and clinical implications. Psychol Med. 1997 May; 27(3):627-33.
    View in: PubMed
    Score: 0.011
  65. Basal ganglia choline levels in depression and response to fluoxetine treatment: an in vivo proton magnetic resonance spectroscopy study. Biol Psychiatry. 1997 Apr 15; 41(8):837-43.
    View in: PubMed
    Score: 0.011
  66. Folate, vitamin B12, and homocysteine in major depressive disorder. Am J Psychiatry. 1997 Mar; 154(3):426-8.
    View in: PubMed
    Score: 0.011
  67. Attention deficit hyperactivity disorder in childhood among adults with major depression. Psychiatry Res. 1996 Jun 01; 62(3):213-9.
    View in: PubMed
    Score: 0.010
  68. Outpatients with DSM-III-R versus DSM-IV melancholic depression. Compr Psychiatry. 1996 Jan-Feb; 37(1):37-9.
    View in: PubMed
    Score: 0.010
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.